Serum markers in skin melanoma--preliminary study

Area of Science:

• Oncology
• Biochemistry
• Dermatology

Background:

• Skin melanoma is a highly aggressive cancer with a significant mortality rate.
• Early detection and monitoring are crucial for improving patient outcomes in melanoma.
• Serum biomarkers offer a non-invasive approach to assess disease status.

Purpose of the Study:

• To investigate the diagnostic and prognostic value of serum S100B and melanoma inhibitory activity (MIA) in skin melanoma.
• To correlate serum marker levels with different stages of melanoma development and metastasis.
• To assess the potential of these markers in monitoring disease progression.

Main Methods:

• A longitudinal study involving 51 skin melanoma patients and 72 healthy volunteers.
• Serum samples were analyzed using standard enzyme-linked immunosorbent assay (ELISA) for S100B and MIA.
• Statistical analysis was performed to compare marker levels across disease stages.

Main Results:

• Serum S100B levels were significantly elevated only in stage IV melanoma patients.
• Serum MIA levels showed significant differences from normal values as early as stage II.
• Both markers' dynamics correlated with melanoma evolution, particularly MIA, indicating potential for disease monitoring.

Conclusions:

• Serum MIA is a more sensitive marker for early-stage melanoma detection compared to S100B.
• Combined elevated levels of S100B and MIA may indicate advanced disease and metastatic potential.
• These serum markers show promise for non-invasive monitoring of skin melanoma progression.